ABBV Logo

AbbVie Inc. (ABBV) 

NYSE
Market Cap
$355.98B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
404 of 776
Rank in Industry
8 of 10

Largest Insider Buys in Sector

ABBV Stock Price History Chart

ABBV Stock Performance

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with …

Insider Activity of AbbVie Inc.

Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $143.55M worth of AbbVie Inc. stock.

On average, over the past 5 years, insiders at AbbVie Inc. have bought $667,072 and sold $84.6M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.

List of Insider Buy and Sell Transactions, AbbVie Inc.

2024-08-05SaleEXECUTIVE CHAIRMAN OF BOARD
66,500
0.0038%
$186.52$12.4M+5.42%
2024-07-17SaleEXECUTIVE CHAIRMAN OF BOARD
282,845
0.016%
$175.00$49.5M+10.72%
2024-03-20SaleEVP, CHIEF BUS/STRAT OFFICER
21,082
0.0012%
$176.30$3.72M+0.70%
2024-03-18SaleEVP, CHIEF COMMERCIAL OFFICER
58,949
0.0033%
$178.79$10.54M-0.57%
2024-03-01SaleEVP, CHIEF HR OFFICER
75,680
0.0042%
$177.27$13.42M-0.12%
2024-02-29SalePRES & CHIEF OPERATING OFFICER
68,879
0.0039%
$176.45$12.15M+1.65%
2024-02-29SaleEVP, GC AND SECRETARY
9,891
0.0006%
$177.39$1.75M+1.65%
2024-02-29SaleSVP, CONTROLLER
5,144
0.0003%
$176.65$908,688+1.65%
2024-02-28SaleCHAIRMAN OF THE BOARD AND CEO
138,616
0.0078%
$177.27$24.57M+0.35%
2024-02-23SaleEVP, GC AND SECRETARY
13,753
0.0008%
$177.51$2.44M+0.40%
2024-02-23SaleEVP, CHIEF FINANCIAL OFFICER
14,140
0.0008%
$177.44$2.51M+0.40%
2024-02-21SaleEVP, CHIEF OPERATIONS OFFICER
52,870
0.003%
$173.71$9.18M+1.94%
2023-12-26SaleEVP, CHIEF BUS/STRAT OFFICER
2,912
0.0002%
$154.72$450,545+12.83%
2023-08-01SaleCHAIRMAN OF THE BOARD AND CEO
60,000
0.0035%
$148.58$8.91M+8.24%
2023-07-31SaleCHAIRMAN OF THE BOARD AND CEO
18,500
0.0011%
$149.15$2.76M+7.42%
2023-04-25SaleSVP, US COMMERCIAL OPERATIONS
6,130
0.0003%
$165.00$1.01M-8.43%
2023-04-17SaleSVP, US COMMERCIAL OPERATIONS
7,499
0.0004%
$161.67$1.21M-6.32%
2023-04-03Sale
15,002
0.0008%
$160.03$2.4M-5.03%
2023-04-03Sale
3,520
0.0002%
$160.00$563,200-5.03%
2023-03-13Sale
53,125
0.003%
$152.28$8.09M+0.29%

Insider Historical Profitability

26.4%
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER
60941
0.0035%
$201.5418+37.99%
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
55903
0.0032%
$201.5412+35.4%
Schumacher Laura JVice Chairman
213003
0.0121%
$201.54114+27.78%
CHASE WILLIAM JEVP, Finance & Administration
169552
0.0096%
$201.5417+28.08%
Gosebruch Henry OEVP, Chief Strategy Officer
41623
0.0024%
$201.5416+30.67%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$31.03B9.65170.38M+6.22%+$1.82B0.57
BlackRock$26.03B8.1142.96M-0.16%-$40.72M0.57
State Street$14.2B4.4277.97M-0.29%-$41.92M0.58
JPMorgan Chase$9.33B2.951.26M-1.08%-$102.03M0.83
Capital International Investors$8.76B2.7248.1M+6.91%+$566.44M1.78
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.